Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiagabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 10/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiagabine SCHEMBL3272861 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL34653 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL41860 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL18496408 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL7346237 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL3958156 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL17493682 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL5164417 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL1527642 | 0.98 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| SCHEMBL9773551 | 0.95 | SLC6A1 (0.90) | SLC6A1PTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290486-B1 | Compositions and methods for the treatment of epilepsy | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-22 | — | — | US | claimed |
| EP-2846795-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY | Cellixbio Private Limited (IN) | 2015-03-18 | — | — | EP | claimed |
| WO-2013167986-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY | KANDULA MAHESH (IN) | 2013-11-14 | — | — | WO | claimed |
| EP-0912091-B1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-12-19 | — | — | EP | claimed |
| EP-0912091-A4 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1142584-A1 | COMPOSITIONS FOR TREATING FREQUENT URINATION AND URINARY INCONTINENCE | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | claimed |
| US-6121290-A | TREATING COUGH BY ADMINISTERING A COMPOUND THAT INHIBITS GABA (GAMMA-AMINO-BUTYRIC ACID) UPTAKE, SUCH AS GUVACINE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-19 | — | — | US | claimed |
| JP-2000511538-A | — | — | 2000-09-05 | — | — | JP | claimed |
| EP-0912091-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1997043902-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-27 | — | — | WO | claimed |
| US-9290486-B1 | Compositions and methods for the treatment of epilepsy | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-22 | — | — | US | disclosed |
| US-9290486-B1 | Compositions and methods for the treatment of epilepsy | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-22 | — | — | US | disclosed |
| US-20150366852-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | N-GENE RESEARCH LABORATORIES, INC. | 2015-12-24 | — | — | US | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-1992017473-A1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-10-15 | — | — | WO | disclosed |
| EP-0236342-B1 | AMINO ACID DERIVATIVES | NOVO NORDISK A/S (DK) | 1991-09-11 | — | — | EP | disclosed |
| US-5010090-A | N-(butenyl substituted) azaheterocyclic carboxylic acids | NOVO NORDISK A/S. (DK) | 1991-04-23 | — | — | US | disclosed |
| EP-0236342-A1 | AMINO ACID DERIVATIVES. | NOVO INDUSTRI AS (DK) | 1987-09-16 | — | — | EP | disclosed |
| WO-1987000171-A1 | AMINO ACID DERIVATIVES | NOVO INDUSTRI A/S (DK) | 1987-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366852-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | GRM5, GRIK5, GRIN2A | SLC6A1 77/4885PTGS1 2622/4885PDE4A 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.